AxTalis vision on Market Access in the greater BENELUX region is to broaden the perspective of patients to access therapeutic solutions in a sustainable manner by collaborating closely with physicians, researchers, companies, health authorities and patients.
Supporting the development of the plans, deliverables, and organizational requirements for commercial success, AxTalis is a consulting agency that focuses on holistic and sustainable market access strategies and launch implementation for academia, pharmaceutical and device companies.
Our Regulatory Affairs services include healthcare policy and all aspects related to obtaining and maintaining registration of therapeutic solutions.
Market Access services include strategic positioning, pricing, and reimbursement dossiers, HEOR and managed entry agreements both on a country level as in the Joint HTA assessment BENELUXAI.
Services for Medical Affairs include creation and implementation of materials and projects supporting scientific engagement, data generation (RWE) and scientific/market/stakeholder insights.
Flexible staffing allows us to provide temporary FTEs to companies on a time or project basis.

Biodimed Conseils is a French consulting company specialized in market access of drugs including Orphan drug, gene and cell therapy, medical devices, acts and diagnosis. The company was founded in 2015 and is based in Paris.
Biodimed Conseils offers to its customer a comprehensive service for health care products (pharmaceuticals and medical devices or technologies) through their life cycle, and performs projects combining its intimate knowledge and understanding of the Health Care Systems and its expertise in medical and economic evaluation.
The team of consultants with a pharmaceutic background and trained in health economic is able to support pharmaceutical companies from the early market access to the price negotiation.
Biodimed has strong knowledge of process and stakeholder within French HTA and public health agencies enabling to deal with complex regulatory or market access issues and to set the most appropriate strategy.

FIECON is a London, UK based health economics consultancy committed to launching products with our pharmaceutical and medical device partners that make a difference in people’s lives. We pursue this objective by generating and communicating the evidence necessary to enable funding agencies and regulators to make fair, efficient decisions about how to allocate scarce healthcare resources to enhance patients’ lives. Since 2018, we have completed over 120 HTA submissions with a 96% success rate of gaining patient access at commercially acceptable prices.
FIECON’s success is a result of our extensive experience synthesizing evidence, designing, building, and quality checking economic models, devising and implementing pricing and market access strategies, and communicating economic value. We have a unique model building platform and partnership approach with our clients which allows us to tackle the dynamic challenges in commercialisation and achieve optimal results in the critical UK marketplace.

Health Access Agency’s (H2A’s) mission is to develop and implement innovative, workable access solutions for biopharma/biotech companies in order to get improved treatment options to patients as soon as possible. Health Access Agency was founded in Zurich in 2014 with an office in the Greater Copenhagen area as well. Throughout the years, the operating model has been to have the right expertise for the project at hand. A key component has been the H2A Network, and now the Pharos Network, with senior market access experts in the core European countries. H2A is working within a European context with special emphasize on the four Nordic markets.

Spanish National Health System is regionalized, P&R decisions are a central level but access decisions relies in the regions and ultimately to hospitals and primary care centers. Omakase Consulting is a specialised strategic consultancy company that can be the best partner for medium and small size pharmaceutical companies who want to achieve successful and timely Pricing and Market Access (PMA) of their products in Spain. Omakase Consulting have large experience in P&R submissions and negotiations at central level and providing optimal market access (MA) strategies at regional and local level. We are experts in Health Economics, PROs and we extensively use Multi-Criteria Decision Analysis (MCDA) for healthcare evaluation and PMA decision-making. We are committed to deliver our best Omakase to increase the patient chances to get their treatments as early as possible.

Regulatory Pharma Net (RPN), founded in 1999, is a qualified pharmaceutical service and consulting company based in Italy. RPN highly qualified and experienced team can provide complete support for a successful access to the Italian market, from development to registration, local access and life cycle management.
RPN has experience with a wide range of therapeutic areas and particularly with orphan and advanced-therapy medicinal products. RPN support includes early access and P&MA strategic assessments, advisory boards, stakeholder management and full support with national and regional P&R negotiations.

Every patient shall have a fast access to the best possible therapy at a fair price.
For national and international pharmaceutical and medical technology manufacturers, who seek a fast and extensive Market Access at a fair price or strive to maintain an adequate price in their existing market, SmartStep is the consulting company of your choice. SmartStep focuses on the very complex and highly regulated German market and quickly and dynamically develops convincing strategies for all phases and challenges of Market Access. The foundation of SmartStep’s competence is the long-time experience working in the international pharmaceutical industry. Therefore, SmartStep not only performs tasks, but excels at delivering solutions.